Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.75 - $10.24
Previous CloseN/A
Volume16.99K
Average Volume (3M)118.91K
Market Cap
N/A
Enterprise Value$67.12M
Total Cash (Recent Filing)$4.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 08, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding16,724,998
10 Day Avg. Volume60,725
30 Day Avg. Volume118,907
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)31.44
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.23
Enterprise Value/Ebitda-5.92
Forecast
1Y Price Target
$15.00Price Target Upside128.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Coya Therapeutics, Inc. News
PremiumCompany Announcements
Coya Therapeutics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Coya Therapeutics Reports 2024 Financial Results and Updates
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company's COYA 301 (low-dose recombinant IL-2) drug candidate aims to selectively expand the Treg population in vivo in order to enhance its suppressive function and to restore immune system homeostasis.
Financial SupportCoya Therapeutics receives a one-time, non-dilutive funding of $3.85 million from Dr. Reddy's, providing immediate financial certainty for its clinical trial.
Regulatory EngagementProductive meetings with the FDA have helped inform the design of the forthcoming phase II study for COYA 302, showcasing strong regulatory engagement.
Bears Say
Market CompetitionThe COYA-303 program may become a new focus of investor interest due to the current excitement over all things incretin.
Pipeline RisksThe planned trial to combine a GLP-1-axis drug with low-dose IL-2 seems interesting due to the significant anti-inflammatory effects of both drugs.
Trial DependencyCoya's P2b trial in ALS is about to start, and investor interest in pipeline programs is leveraged to that readout.
---
Ownership Overview
23.00% Insiders
5.73% Mutual Funds
18.96% Other Institutional Investors
47.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $4.75 and its highest was $10.24 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Mar 18, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.095.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 16,724,998 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -5.839%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
---
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
---
COYA Stock 12 Month Forecast
Average Price Target
$15.00
▲(128.66% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Anavex Life Sciences
―
Axsome Therapeutics
―
Annovis Bio
―
Best Analysts Covering COYA
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+39.02%
reiterated a buy rating 5 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +39.02% per trade.
---